BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 30181420)

  • 1. Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer.
    Rocque GB; Williams CP; Jackson BE; Ingram SA; Halilova KI; Pisu M; Kenzik KM; Azuero A; Forero A; Bhatia S
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1084-1091. PubMed ID: 30181420
    [No Abstract]   [Full Text] [Related]  

  • 2. Concordance with NCCN treatment guidelines: Relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasis.
    Rocque GB; Williams CP; Kenzik KM; Jackson BE; Azuero A; Halilova KI; Ingram SA; Pisu M; Forero A; Bhatia S
    Cancer; 2018 Nov; 124(21):4231-4240. PubMed ID: 30317547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
    Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
    Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage I-III Breast Cancer.
    Hsieh MC; Zhang L; Wu XC; Davidson MB; Loch M; Chen VW
    J Natl Compr Canc Netw; 2019 Jun; 17(6):676-686. PubMed ID: 31200362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare Utilization and Costs During the Initial Phase of Care Among Elderly Women With Breast Cancer.
    Vyas A; Madhavan SS; Sambamoorthi U; Pan XL; Regier M; Hazard H; Kalidindi S
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1401-1409. PubMed ID: 29118232
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of Guideline-Discordant Treatment on Cost and Health Care Utilization in Older Adults with Early-Stage Breast Cancer.
    Williams CP; Kenzik KM; Azuero A; Williams GR; Pisu M; Halilova KI; Ingram SA; Yagnik SK; Forero A; Bhatia S; Rocque GB
    Oncologist; 2019 Jan; 24(1):31-37. PubMed ID: 30120157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guideline-Concordant Treatment Among Elderly Women With HER2-Positive Metastatic Breast Cancer in the United States.
    Vyas AM; Aroke H; Kogut S
    J Natl Compr Canc Netw; 2020 Apr; 18(4):405-413. PubMed ID: 32259787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guideline Discordance and Patient Cost Responsibility in Medicare Beneficiaries With Metastatic Breast Cancer.
    Williams CP; Azuero A; Kenzik KM; Pisu M; Nipp RD; Bhatia S; Rocque GB
    J Natl Compr Canc Netw; 2019 Oct; 17(10):1221-1228. PubMed ID: 31590153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall survival, costs and healthcare resource use by number of regimens received in elderly patients with newly diagnosed metastatic triple-negative breast cancer.
    Aly A; Shah R; Hill K; Botteman MF
    Future Oncol; 2019 Mar; 15(9):1007-1020. PubMed ID: 30717602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receipt of Guideline-Concordant Care Among Older Women With Stage I-III Breast Cancer: A Population-Based Study.
    LeMasters T; Madhavan SS; Sambamoorthi U; Hazard-Jenkins HW; Kelly KM; Long D
    J Natl Compr Canc Netw; 2018 Jun; 16(6):703-710. PubMed ID: 29891521
    [No Abstract]   [Full Text] [Related]  

  • 11. Radiotherapy Utilization for Patients Over Age 60 With Early Stage Breast Cancer.
    Paulsson AK; Fowble B; Lazar AA; Park C; Sherertz T
    Clin Breast Cancer; 2020 Apr; 20(2):168-173. PubMed ID: 31744755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of guideline-concordant initial systemic treatment with clinical and economic outcomes among older women with metastatic breast cancer in the United States.
    Vyas A; Mantaian T; Kamat S; Kurian S; Kogut S
    J Geriatr Oncol; 2021 Sep; 12(7):1092-1099. PubMed ID: 34099411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States.
    Poorvu PD; Vaz-Luis I; Freedman RA; Lin NU; Barry WT; Winer EP; Hassett MJ
    Breast Cancer Res Treat; 2018 Apr; 168(3):727-737. PubMed ID: 29332137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
    Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
    Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data.
    Lang K; Huang H; Sasane M; Paly VF; Hao Y; Menzin J
    BMC Health Serv Res; 2014 Jul; 14():298. PubMed ID: 25008431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma.
    Aly A; Johnson C; Yang S; Botteman MF; Rao S; Hussain A
    J Med Econ; 2019 Jul; 22(7):662-670. PubMed ID: 30836812
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical and economic outcomes associated with adjuvant chemotherapy in elderly patients with early stage operable breast cancer.
    Sail KR; Franzini L; Lairson DR; Du XL
    Value Health; 2012 Jan; 15(1):72-80. PubMed ID: 22264974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea.
    Kim HK; Lee SH; Kim YJ; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Ahn JS; Im YH; Yu JH; Park YH
    BMC Cancer; 2019 Jan; 19(1):84. PubMed ID: 30654765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variations in Guideline-Concordant Breast Cancer Adjuvant Therapy in Rural Georgia.
    Guy GP; Lipscomb J; Gillespie TW; Goodman M; Richardson LC; Ward KC
    Health Serv Res; 2015 Aug; 50(4):1088-108. PubMed ID: 25491350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Impact of 21-Gene Recurrence Score Test Within the Veterans Health Administration: Utilization and Receipt of Guideline-Concordant Care.
    Hull LE; Lynch JA; Berse BB; DuVall SL; Chun DS; Venne VL; Efimova OV; Icardi MS; Kelley MJ
    Clin Breast Cancer; 2018 Apr; 18(2):135-143. PubMed ID: 29306660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.